Taxol Weekly More Effective with Less Side Effects than Taxotere Weekly or Every Three Weeks

A recent study found that getting paclitaxel (Taxol) weekly had more benefits than getting paclitaxel​ every 3 weeks for women diagnosed with breast cancer that had spread to the lymph nodes or women diagnosed with breast cancer that hadn’t spread to the lymph nodes but was considered high risk. Getting paclitaxel​ every week also had more benefits than getting Docetaxel (Taxotere)​ weekly or every 3 weeks for these women without the side effect of permanent or persistent hair loss or long term thinning hair.

Find out if you qualify for compensation if you have suffered permanent hair loss or long term thinning hair following chemotherapy for breast cancer.

In this study of 5,000 women, more women who received paclitaxel​ once a week were likely to be alive and free of breast cancer 5 years after being diagnosed compared to women who received paclitaxel​ every 3 weeks OR women who received Docetaxel​ (either weekly or every 3 weeks). All the women received doxorubicin and cyclophosphamide before receiving either paclitaxel​ or Docetaxel​.

For women diagnosed with early-stage, lymph-node-positive breast cancer, treatment often includes chemotherapy with Adriamycin and Cytoxan followed by a taxane. This chemotherapy regimen is sometimes called AC followed by T. paclitaxel​, Docetaxel​, and albumin-bound or nab-paclitaxel are all taxanes. In the AC followed by T regimen, a taxane is usually given as 4 treatments over 12 weeks — 1 treatment every 3 weeks.

In this study, the researchers compared the usual schedule of giving paclitaxel​ or Docetaxel​ every 3 weeks to a different schedule that gave a lower dose of paclitaxel​ or Docetaxel​ every week for 12 weeks. The women who got paclitaxel​ every week were 27% more likely to be alive and free of breast cancer 5 years after diagnosis compared to those who received the standard paclitaxel​ treatment schedule. The women who got paclitaxel​ every week also were more likely to be alive 5 years after diagnosis compared to women who got Docetaxel​ (either weekly or every 3 weeks). Albumin-bound or nab-paclitaxel​ was not looked at in this study.

For each medicine and treatment schedule the chances of being alive 5 years after diagnosis are:

  • Paclitaxel​ once a week: 89.7%
  • Paclitaxel​ once every 3 weeks: 86.5%
  • Docetaxel​ once every 3 weeks: 87.3%
  • Docetaxel​ once a week: 86.2%

Some doctors have wondered whether a taxane has benefits for women diagnosed with hormone-receptor-positive breast cancer. This study found that women diagnosed with hormone-receptor-positive breast cancer did benefit from getting a taxane.

Women who got Paclitaxel​ or Docetaxel​ once a week instead of every 3 weeks seemed to have less severe side effects from the chemotherapy. This is probably because each Paclitaxel​ or Docetaxel​ dose was slightly less than half the standard dose. On the other hand, these women had to get treatment every week instead of every 3 weeks. It may be harder to plan your life around getting treatment every week than getting treatment every 3 weeks.

If chemotherapy that includes a taxane is going to be a part of your treatment plan, you might want to talk to your doctor about this study and consider asking these questions:

  • Which taxane (Paclitaxel​, Docetaxel​, or Abraxane) is recommended for me?
  • Which treatment schedule (weekly or every 3 weeks) is recommended?